HC Wainwright Predicts Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Inozyme Pharma in a research report issued on Friday, January 10th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05.

INZY has been the topic of several other research reports. Wedbush reissued an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, Raymond James began coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.25.

Inozyme Pharma Trading Down 28.6 %

Shares of NASDAQ INZY opened at $2.00 on Monday. The stock has a market capitalization of $128.48 million, a P/E ratio of -1.28 and a beta of 1.35. Inozyme Pharma has a 1-year low of $1.97 and a 1-year high of $7.80. The business’s 50 day moving average is $3.02 and its two-hundred day moving average is $4.38. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

Institutional Investors Weigh In On Inozyme Pharma

Several hedge funds have recently made changes to their positions in INZY. Eventide Asset Management LLC raised its holdings in shares of Inozyme Pharma by 5.0% in the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after acquiring an additional 198,216 shares in the last quarter. Samlyn Capital LLC raised its holdings in shares of Inozyme Pharma by 15.0% in the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after purchasing an additional 437,622 shares in the last quarter. State Street Corp raised its holdings in shares of Inozyme Pharma by 5.0% in the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company’s stock valued at $5,494,000 after purchasing an additional 50,386 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Inozyme Pharma by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock worth $6,126,000 after purchasing an additional 19,499 shares during the period. Finally, Barclays PLC boosted its stake in shares of Inozyme Pharma by 261.4% during the third quarter. Barclays PLC now owns 76,730 shares of the company’s stock valued at $401,000 after purchasing an additional 55,497 shares in the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.